Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
Papakonstantinou A, Gonzalez NS, Pimentel I, Suñol A, Zamora E, Ortiz C, Espinosa-Bravo M, Peg V, Vivancos A, Saura C, Villacampa G, Oliveira M. Papakonstantinou A, et al. Among authors: zamora e. Cancer Treat Rev. 2022 Mar;104:102362. doi: 10.1016/j.ctrv.2022.102362. Epub 2022 Feb 18. Cancer Treat Rev. 2022. PMID: 35219090 Review.
Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response.
Ciriaco N, Zamora E, Escrivá-de-Romaní S, Miranda Gómez I, Jiménez Flores J, Saura C, Sloane H, Starus A, Fredebohm J, Georgieva L, Speight G, Jones F, Ramón Y Cajal S, Espinosa-Bravo M, Peg V. Ciriaco N, et al. Among authors: zamora e. Ther Adv Med Oncol. 2022 Nov 29;14:17588359221139601. doi: 10.1177/17588359221139601. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36479470 Free PMC article.
RAGE/SNAIL1 signaling drives epithelial-mesenchymal plasticity in metastatic triple-negative breast cancer.
Pujals M, Mayans C, Bellio C, Méndez O, Greco E, Fasani R, Alemany-Chavarria M, Zamora E, Padilla L, Mitjans F, Nuciforo P, Canals F, Nonell L, Abad M, Saura C, Tabernero J, Villanueva J. Pujals M, et al. Among authors: zamora e. Oncogene. 2023 Aug;42(35):2610-2628. doi: 10.1038/s41388-023-02778-4. Epub 2023 Jul 19. Oncogene. 2023. PMID: 37468678
Epstein-Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report.
Aran A, Peg V, Rabanal RM, Bernadó C, Zamora E, Molina E, Arribas YA, Arribas J, Pérez J, Roura-Mir C, Carrascal M, Cortés J, Martí M. Aran A, et al. Among authors: zamora e. Front Immunol. 2021 Nov 16;12:761798. doi: 10.3389/fimmu.2021.761798. eCollection 2021. Front Immunol. 2021. PMID: 34868006 Free PMC article.
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.
Pascual T, Cejalvo JM, Oliveira M, Vidal M, Vega E, Ganau S, Julve A, Zamora E, Miranda I, Delgado A, Bermejo B, la Cruz-Merino L, Juan M, Ferrero-Cafiero JM, Canes J, Gonzalez X, Villagrasa P, Prat A. Pascual T, et al. Among authors: zamora e. Future Oncol. 2020 Aug;16(24):1801-1813. doi: 10.2217/fon-2020-0246. Epub 2020 Jul 7. Future Oncol. 2020. PMID: 32633563
High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer.
Quintela-Fandino M, Bermejo B, Zamora E, Moreno F, García-Saenz JÁ, Pernas S, Martínez-Jañez N, Jiménez D, Adrover E, de Andrés R, Mourón S, Bueno MJ, Manso L, Viñas G, Alba E, Llombart-Cussac A, Cortés J, Tebar C, Roe DJ, Grant A, Watson A, Colomer R, Mouneimne G. Quintela-Fandino M, et al. Among authors: zamora e. Clin Cancer Res. 2024 Nov 15;30(22):5094-5104. doi: 10.1158/1078-0432.CCR-24-1518. Clin Cancer Res. 2024. PMID: 39283720 Clinical Trial.
292 results